Literature DB >> 14998226

Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature.

Miranda R Andrus1.   

Abstract

A 67-year-old man receiving a stable maintenance dosage of warfarin experienced an increased international normalized ratio (INR) without bleeding when his atorvastatin therapy was switched to fluvastatin. His warfarin dosage was reduced and his INR stabilized. The fluvastatin was switched back to atorvastatin, and the warfarin dosage was increased to maintain the patient's goal INR. The literature supports a drug interaction between warfarin and fluvastatin due to the strong affinity of fluvastatin for the cytochrome P450 enzyme 2D6. This interaction has not been seen with atorvastatin. Lovastatin also reportedly has caused increases in INR when coadministered with warfarin. It is unclear whether simvastatin interacts with warfarin, but it may increase INRs slightly or increase serum simvastatin levels. One case report describes an interaction between simvastatin and the anticoagulant acenocoumarol, which resulted in an elevated INR. Pravastatin does not appear to interact with warfarin but has caused an increased INR when combined with the anticoagulant fluindione. Thus, until more definitive data are available, clinicians should monitor the INR closely after starting statin therapy in any patient receiving anticoagulation therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14998226     DOI: 10.1592/phco.24.2.285.33137

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  17 in total

1.  Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis.

Authors:  Edith A Nutescu; Cathy M Helgason
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-07

Review 2.  Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.

Authors:  Edith Nutescu; Ittiporn Chuatrisorn; Erika Hellenbart
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

Review 3.  PharmGKB summary: very important pharmacogene information for CYP4F2.

Authors:  Maria L Alvarellos; Katrin Sangkuhl; Roxana Daneshjou; Michelle Whirl-Carrillo; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-01       Impact factor: 2.089

4.  CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.

Authors:  Matthew G McDonald; Mark J Rieder; Mariko Nakano; Clara K Hsia; Allan E Rettie
Journal:  Mol Pharmacol       Date:  2009-03-18       Impact factor: 4.436

Review 5.  Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.

Authors:  Pertti J Neuvonen; Janne T Backman; Mikko Niemi
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

6.  Mortality and Associated Morbidities Following Traumatic Brain Injury in Older Medicare Statin Users.

Authors:  Bilal Khokhar; Linda Simoni-Wastila; Julia F Slejko; Eleanor Perfetto; Min Zhan; Gordon S Smith
Journal:  J Head Trauma Rehabil       Date:  2018 Nov/Dec       Impact factor: 2.710

7.  The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose.

Authors:  Darja Herman; Igor Locatelli; Iztok Grabnar; Polona Peternel; Mojca Stegnar; Mitja Lainscak; Ales Mrhar; Katja Breskvar; Vita Dolzan
Journal:  Eur J Clin Pharmacol       Date:  2006-03-22       Impact factor: 2.953

8.  The Safety and Efficacy of Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Systematic Review and Meta-analysis.

Authors:  Yang Hua; Jin-Yu Sun; Yue Su; Qiang Qu; Hong-Ye Wang; Wei Sun; Xiang-Qing Kong
Journal:  Am J Cardiovasc Drugs       Date:  2021-01       Impact factor: 3.571

9.  Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk.

Authors:  Hedi Schelleman; Warren B Bilker; Colleen M Brensinger; Fei Wan; Yu-Xiao Yang; Sean Hennessy
Journal:  Am J Med       Date:  2010-02       Impact factor: 4.965

10.  Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.

Authors:  Toshiyuki Sakaeda; Hideki Fujino; Chiho Komoto; Mikio Kakumoto; Jiang-Shu Jin; Koichi Iwaki; Kohshi Nishiguchi; Tsutomu Nakamura; Noboru Okamura; Katsuhiko Okumura
Journal:  Pharm Res       Date:  2006-01-01       Impact factor: 4.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.